Qinlock (ripretinib) is indicated to treat adult patients with advanced gastrointestinal stromal tumors (GIST). The drug from Qinlock won FDA approval on May 15, 2020. In the Phase 3 INVICTUS study, the drug demonstrated clinical benefits with dose escalation for patients with advanced gastrointestinal stromal tumors with disease progression.